IRIS
PIETRA, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 302
EU - Europa 209
AS - Asia 116
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 289
IE - Irlanda 122
CN - Cina 98
DE - Germania 23
FI - Finlandia 23
SG - Singapore 16
IT - Italia 15
SE - Svezia 14
CA - Canada 13
GB - Regno Unito 6
NL - Olanda 3
IN - India 2
MU - Mauritius 2
AU - Australia 1
CL - Cile 1
ES - Italia 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 631
Salva come PNG Salva come JPEG
Città #
Dublin 122
Chandler 72
Beijing 37
New York 28
Ashburn 27
Boardman 18
Helsinki 17
Lawrence 14
Princeton 14
Nanjing 13
Toronto 12
Shanghai 11
Wilmington 11
Medford 10
Singapore 9
Nanchang 6
Hangzhou 5
Hebei 5
Jacksonville 5
Jiaxing 5
Changsha 4
Gallarate 4
Norwalk 4
Shenyang 4
Washington 4
Falls Church 3
Tianjin 3
Dronten 2
Falkenstein 2
Jinan 2
Monmouth Junction 2
Rome 2
Seattle 2
Woodbridge 2
Berlin 1
Canberra 1
Clifton 1
Fairfield 1
Fano 1
Fuzhou 1
Leawood 1
Los Angeles 1
Milan 1
Modena 1
Montesilvano Marina 1
Ningbo 1
Pavia 1
Pune 1
San Francisco 1
Settimo Torinese 1
Totale 497
Salva come PNG Salva come JPEG
Nome #
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 56
Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation 54
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 49
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 47
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 46
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 44
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 43
Diagnosis and management of prefibrotic myelofibrosis. 43
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 35
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 35
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. 33
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 33
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 30
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. 28
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications 13
Totale 654
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202055 0 0 0 0 0 0 5 9 8 18 13 2
2020/202122 1 0 1 3 0 1 0 2 9 1 2 2
2021/202277 0 0 12 3 3 3 1 4 4 5 11 31
2022/2023248 26 16 6 8 15 19 0 17 130 3 7 1
2023/2024137 15 30 7 8 5 54 1 10 1 1 3 2
2024/202539 15 18 5 1 0 0 0 0 0 0 0 0
Totale 654